[
    [
        {
            "time": "2023-03-15",
            "original_text": "AbbVie's Imbruvica Fails in Phase III Pancreatic Cancer Study",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Imbruvica",
                    "Phase III",
                    "Pancreatic Cancer",
                    "Study"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "AbbVie's Imbruvica Fails in Phase III Pancreatic Cancer Study",
                "Correlation": 9,
                "Sentiment": 2,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-03-15",
            "original_text": "What's in Store for Bristol-Myers (BMY) in Q4 Earnings?",
            "features": {
                "keywords": [
                    "Bristol-Myers",
                    "Q4",
                    "Earnings"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "What's in Store for Bristol-Myers (BMY) in Q4 Earnings?",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-03-15",
            "original_text": "Zacks Value Trader Highlights: Crocs, Five Below, AbbVie and J.Jill",
            "features": {
                "keywords": [
                    "Zacks",
                    "Value Trader",
                    "Crocs",
                    "Five Below",
                    "AbbVie",
                    "J.Jill"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "retail",
                    "healthcare",
                    "consumer goods"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Zacks Value Trader Highlights: Crocs, Five Below, AbbVie and J.Jill",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        }
    ]
]